कंपनी का अवलोकन
Bionano Genomics, Inc. operates as a provider of genome analysis solutions serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company specializes in offering genome analysis software designed to enable genomics laboratories to analyze and interpret data across various platforms, positioning itself within the broader healthcare sector. Specifically, it functions in the medical instruments and supplies industry, which typically involves the manufacturing or distribution of diagnostic tools and specialized equipment. In terms of scale, the company carries a market capitalization of $12.87M with total annual revenue of $28.51M and employs 95 individuals. These valuation and revenue figures indicate that Bionano Genomics is a small-cap entity with a modest revenue footprint relative to large-cap healthcare peers, suggesting a niche operational scope rather than broad market dominance. The low market cap combined with the specific employee count highlights a lean organizational structure typical of early-stage or specialized technology firms seeking to establish market share in the genomics space.
वित्तीय स्वास्थ्य
The company reported a revenue of $28.51M over the trailing twelve months, yet recorded a net income of $-26,395,000 and an EBITDA of $-23,812,000. The significant disparity between the positive revenue of $28.51M and the substantial net loss reveals a cost structure where operating expenses and other costs far exceed gross profits, resulting in a net income that is negative by more than nine times the total revenue. Free cash flow stands at $-4,575,125, indicating that the company is burning cash at a rate that could limit its financial flexibility and ability to fund operations without external capital injections. Margin analysis shows a gross margin of 46.2%, which suggests a healthy pricing power or cost advantage at the production level, but this is eroded by high operating costs to yield an operating margin of -107.4% and a profit margin of -92.6%. The negative operating and profit margins indicate that the company is currently unprofitable on a total business basis, with costs consuming more than the entire revenue base in some periods. On the balance sheet, the company holds $19.27M in cash against $16.89M in debt, resulting in a debt-to-equity ratio of 38.03, which implies a highly leveraged position relative to equity, though absolute debt levels are manageable against available cash. The current ratio is 1.98, which indicates that the company possesses nearly double the current assets needed to cover its short-term liabilities, suggesting adequate short-term liquidity despite the overall cash burn. Return on Equity is -66.2% and Return on Assets is -27.7%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and in the asset base, reflecting the challenges of scaling a loss-making business.
मूल्यांकन आकलन
Trailing P/E ratio is N/A due to the negative earnings, while the forward P/E stands at -1.05, a metric that reflects the current unprofitability and the market's inability to value the stock on a standard earnings multiple basis at this time. The price-to-book ratio is 0.28, indicating that the market values the company at a significant discount to its book value, suggesting a lack of market premium over the net asset value recorded on the balance sheet. The price-to-sales ratio is 0.45 and the EV/EBITDA is -0.44, which are alternative valuation metrics suggesting the stock is priced based on revenue rather than earnings, a common characteristic for unprofitable biotechnology or medical instrument firms. The 52-week high is $5.50 and the 52-week low is $1.06, meaning the stock has experienced extreme volatility with a trading range of over four hundred percent. The beta value is 1.60, which signifies that the stock's price volatility is significantly higher than the broader market, moving roughly 60% more aggressively than the market average during periods of fluctuation. These valuation metrics collectively paint a picture of a high-risk, high-volatility asset where traditional valuation models are less applicable due to the absence of consistent profitability.
Growth & Income
Revenue growth year-over-year is -2.6% while earnings growth is N/A due to the lack of positive earnings in the prior period. The absence of positive earnings growth means that revenue contraction is the primary driver of financial decline, implying that the company is not growing its top line and is simultaneously facing profitability challenges. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings—or in this case, losses—for reinvestment into growth initiatives or to cover operational deficits. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, positioning the stock purely as a speculative vehicle reliant on future operational turnaround rather than current cash generation or shareholder returns.